Alpha-L-Fucosidase Serves as a Prognostic Indicator for Intrahepatic Cholangiocarcinoma and Inhibits Its Invasion Capacity

Table 1

Relationship between clinicopathological characteristics and serum alpha-L-fucosidase (AFU) level in 148 patients with intrahepatic cholangiocarcinoma (iCCA).

Variables	Number	AFU (U/L)		value
		<20.85	≥20.85
Age (years)
<60	91	45 (69.2)	46 (55.4)	0.087
≥60	57	20 (30.8)	37 (44.6)
Sex
Female	54	23 (35.4)	31 (37.3)	0.623
Male	94	42 (64.6)	52 (62.7)
Lymph node metastasis
No	105	47 (72.3)	58 (69.9)	0.747
Yes	43	18 (27.7)	25 (30.1)
Tumor number
Solitary	95	41 (63.1)	54 (65.1)	0.803
Multiple	53	24 (36.9)	29 (34.9)
ALT (U/L)
≤40	112	51 (78.5)	61 (73.5)	0.485
>40	36	14 (21.5)	22 (26.5)
AST (U/L)
≤45	132	61 (93.8)	71 (85.5)	0.106
>45	16	4 (6.2)	12 (14.5)
Tumor size (cm)
≤5	57	23 (35.4)	34 (41)	0.489
>5	91	42 (64.6)	49 (59)
TNM stage
I	46	24 (36.9)	22 (26.5)	0.174
II–IV	102	41 (63.1)	61 (73.5)
CA19-9 (U/mL)
<100	94	40 (61.5)	54 (65.1)	0.659
≥100	54	25 (38.5)	29 (34.9)

AST: aspartate transaminase; ALT: alanine aminotransferase; CA19-9: carbohydrate antigen 19-9.